Title: Comparing India's second COVID wave with the first wave – a single-center experience

Short title: Second COVID wave is more dangerous than first in India

Authors: Mayank Kapoor, Budha O Singh, Prasan Kumar Panda, Pathik Dhanger, Anant Kataria

Affiliations: Department of Internal Medicine (Infectious Disease Division), All India Institute of Medical Sciences, Rishikesh, India

Emails: mkapoorsonu@yahoo.co.in, budhaoinam@gmail.com, motherprasanna@rediffmail.com, pathik.dhangar415@gmail.com, anant.kataria309@gmail.com

Corresponding author

Prasan Kumar Panda

Asst. Professor, Dept. of Medicine,

Sixth Floor, College Block,

All India Institute of Medical Sciences (AIIMS),

Rishikesh, India, 249203

Mob: +91-9868999488

motherprasanna@rediffmail.com

Key points

Question: What are the differences between the clinical profile of the first wave (W1) and the

second wave (W2) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a

single tertiary care center of India?

Findings: In this observational study among 106 patients in W1 (April-June 2020) and 104

patients in W2 (March-May 2021), there were higher proportion of increased age, oxygen

requirement, ventilator requirement, ICU admission, and organ impairment in the admitted

COVID-19 cases during the second wave.

Meaning: The second wave hits India badly than the first wave and associated with more

fatalities.

Abstract

Background

The COVID-19 pandemic has resurfaced in India in the form of a hard-hitting second wave. This

study aims to compare the clinical profile of the first wave (April-June 2020) and the second

wave (March-May 2021) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

in a single tertiary care center of India. This will help prioritize the target population group and

management strategies in the upcoming third wave if any.

Methods

In this retrospective observational study, we examined the demographic profile, symptoms at

presentation, the severity of illness, baseline investigations, treatments received, underlying

comorbidities, and outcomes of the COVID-19 patients belonging to the first (W1) and the

second wave (W2) of the pandemic in India.

Findings

Among 106 patients in W1 and 104 patients in W2, the age group affected most was 37.1

(SD=16.9) years compared with 50.5 (SD=17.7) years respectively. The baseline oxygen

saturation is lower in W2, being 84·0 (13·4) % compared with 91·9 (7·4) % in W1. 70.2 % of the

cases belonged to the severe category in W2 compared to 37.5% in W1. W2 patients

demonstrated higher transaminase levels [SGOT, 108.3 (99.3) v/s 54.6 (69.3); SGPT, 97.6 (82.3)

v/s 58.7 (69.7)] with respect to W1. Similarly, the CT severity score for W2 [29.5 (6.7)] was

higher than W1 [23·2 (11·5)][All P<0.05]. The proportion of patients requiring oxygen (81.8%)

v/s 11.2%), high flow nasal cannula (11.4% v/s 5.6%), non-invasive ventilation (41.2% v/s

1.5%), invasive ventilation (24.5% v/s 0.9%), as well as ICU/HDU admissions (56.4% v/s

12.0%) was higher for W2 as compared with W1. The measured case fatality rate varies from

29% for W2 to 9.6% for W1.

Interpretation

Higher age, oxygen requirement, ventilator requirement, ICU admission, and organ impairment

are more prevalent in the admitted COVID-19 cases during the second wave that has hit India

compared to the first wave and associated with more fatalities. Strategy for another wave should

be planned accordingly.

Keywords: Coronavirus disease 2019; COVID mutants; Global health; Pandemic waves

Introduction

The Coronavirus disease 2019 (COVID-19) pandemic has taken the whole of the world in its

grip. After initial containment, the virus has re-emerged in many countries very strongly. An

excellent example is India, where after initial control, the second wave has struck more fiercely. The first wave showed a peak in mid-September 2020, with a maximum of about 97,000 cases per day. By January of this year, the daily caseload had decreased to less than 10,000 a day. However, starting from February, India's COVID-19 cases began spiking, rising exponentially to more than four lakh cases per day in April 2021. The daily number of deaths reported also rose from about a minimum of 70 to about 3900 per day. The new variant is termed a "double mutation" variant, referring to mutations in the virus's spike proteins. The mortality rate for the disease in India was 1.1%. Many speculations regarding the age group affected, the oxygen requirement trend, and the associated complications of the second wave (W2) in comparison to the first wave (W1) are there.

This study explores what makes the second wave different from the first, which has led to such an alarming spike of cases in India. We analyzed the data from patients admitted to tertiary care dedicated COVID-19 hospital during April-June 2020 (W1) and March-May 2021 (W2) to find the differences between the two pandemic waves in India.

Methods

Study design and participants

The study was carried out at All India Institute of Medical Sciences (AIIMS), Rishikesh, a tertiary care center catering to North India's population. We retrospectively searched the hospital database and analyzed the records of lab-confirmed COVID-19 patients of at least 18 years of age. Positivity obtained on reverse transcriptase-polymerase chain reaction (RT-PCR) SARS-CoV-2 assay of nasopharyngeal or oropharyngeal swab specimens defined COVID-19 positivity using SD Biosensor standard M nCoV real-time detection kit, Biorad CFX 96 real-time thermocycler, and Thermo flex 96 extractor machine. The biochemical investigations were

performed according to the institutional treatment protocols and standards. The treatment decisions were solely clinician-based according to the protocols. At the time of admission, the patients were divided into different categories according to the severity of the disease. We followed the Ministry of Health and Family Welfare (MoHFW), India guidelines (Table 1).⁵

Table 1: Ministry of Health and Family Welfare (MoHFW) COVID severity categorization ⁵			
Category	Characteristics		
Mild	Without evidence of breathlessness or hypoxia (normal saturation at room air).		
Moderate	Clinical features of dyspnea, including SpO2 <94% (range 90-94%) on room air, Respiratory Rate > 24 per minute		
Severe/Critical	Clinical signs of pneumonia plus one of the following; respiratory rate >30 breaths/min, severe respiratory distress, SpO2 <90% on room air		

Note: SpO2 - Oxygen saturation

We compared the two groups based on their age, health risk factors (smoking status and presence of diabetes and hypertension), severity, and outcomes. We analyzed the number of patients requiring oxygen, non-invasive or invasive ventilation, ICU admissions, and the various treatments. Ethical approval was obtained (CTRI/2020/08/027169).

Statistical analysis

Continuous data following normal distribution and homogeneity of variance was expressed as mean \pm SD. We used χ^2 and Student's t-tests to compare the demographic characteristics of individuals belonging to the two waves. Statistical analysis was done using SPSS version 25. P values <0.05 were considered significant.

Results

Between April 2020 to June 2020 (W1), we analyzed records of 106 patients; and compared them with 104 patients from March 2021 to May 2021 (W2) (Fig. 1). The baseline mean oxygen saturation was found to be lower in W2 (Table 2). We had 70.2 % of the cases belonging to the severe category in W2 compared to 37.5% in W1. W2 patients demonstrated higher transaminase

levels with respect to W1. Similarly, the CT severity score for W2 was also higher than W1. A higher proportion of patients required oxygen, high flow nasal cannula, non-invasive ventilation, invasive ventilation, and ICU/HDU admissions in W2 compared with W1 (Tables 3). COVID mortality was also higher in W2 than W1 (Tables 4).




Fig. 1: The study flow [W1 – First COVID-19 wave (April-June 2020); W2 – Second wave (March-May 2021)]

Table 2: Demographic characteristics of the study population during both COVID-19 waves				
Variable	Sub-group	First Wave (W1)	Second Wave (W2)	
		n=106	n=104	

Sex	Female		
		36 (34.4%)	46 (44.3%)
	Male	70 (65.6%)	58 (55.7%)
Age, years\$		37-1 (16-9)	50.5 (17.7)
Temperature (⁰ F) ^{\$}	98.5 (0.9)	98.8 (1.2)
Heart rate (per	minute) ^{\$}	91.0 (12.3)	92.9 (14.5)
Respiratory rat	te (per minute) ^{\$}	20.0 (3.6)	25·1 (4·7)
SpO2 (%) ^{\$}		91.9 (7.4)	85.5 (13.4)
Severity	Mild	42 (39.8%)	15 (14%)
	Moderate	24 (22.6%)	16 (15.8%)
	Severe	40 (37.5%)	73 (70.2%)
Symptoms	Fever	31 (29.3%)	88 (84.5%)
	Cough	15 (14.2%)	80 (77.5%)
	Sore throat	12 (11.1%)	5 (5%)
	Runny nose (Rhinorrhea)	3 (3%)	3 (3%)
	Shortness of breath (Dyspnea)	16 (15%)	83 (80%)
	Loss of smell / taste (Anosmia/	1 (1%)	4 (4%)
	Aguesia)		
	Fatigue / Malaise	10 (9.5%)	19 (18.6%)
	Diarrhea	12 (11.1%)	5 (5%)
Associations	Hypertension	13 (11.9%)	31 (30.3%)
	Diabetes Mellitus	18 (17.6%)	24 (22.8%)
	Smoking	5 (4.6%)	1 (1%)

Data are expressed as number (percentage) unless otherwise stated

^{\$}Data is expressed as mean (SD)

Table 3: Routine investigations and treatment received during both COVID-19 waves				
Variable	Sub-group	First Wave (W1)	Second Wave (W2)	P-value
		n=106	n=104	
Baseline	Hb (gm/dl)	12.4 (2.6)	12.4 (2.2)	0.9
Investigations	TLC (per mm3)	10062 (13620)	9100 (4600)	0.04
	Lymphocyte count %	24.6 (10.9)	18.1 (18.9)	0.03
	Neutrophil count %	63.1 (16.5)	75.6 (19.7)	<0.001

Platelet count 194-1 (88-9) 200.2 (93.8) 0.7 (thousand/mm3) INR
INR
Total Bilirubin (mg/dl) 1.1 (3.2) 0.7 (0.9) 0.4 AST/SGOT (IU/L) 54.6 (69.3) 108.3 (99.3) 0.001 ALT/SGPT (IU/L) 58.7 (69.7) 97.6 (82.3) 0.007 Creatinine (mg/dl) 1.3 (2.6) 1.1 (0.5) 0.5 CTSS 23·2 (11·5) 29.5 (6.7) 0.005 Supplementation required ⁵ ; 12 (11·2%); 85 (81.8%); 0.5 duration (days) 7.8 (7.1) 8.1 (3.1) HFNC ⁵ ; 6 (5.6%); 12 (11.4%); 1.2 duration (days) 10.1 (6.2) 7.2 (4.3) NIV ⁵ ; 2 (1.5%); 43 (41·2%); 3.5 duration (days) 18.0 (2.0) 6.8 (2.3) Invasive ventilation ⁵ ; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support ⁵ ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ⁵ ; 13 (12%); 59 (56.4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6)
AST/SGOT (IU/L) 54.6 (69.3) 108.3 (99.3) 0.001 ALT/SGPT (IU/L) 58.7 (69.7) 97.6 (82.3) 0.007 Creatinine (mg/dl) 1.3 (2.6) 1.1 (0.5) 0.5 CTSS 23·2 (11·5) 29.5 (6.7) 0.005 Supplementation required ⁵ ; 12 (11·2%); 85 (81.8%); 0.5 duration (days) 7.8 (7.1) 8.1 (3.1) HFNC ⁵ ; 6 (5.6%); 12 (11·4%); 1.2 duration (days) 10.1 (6.2) 7.2 (4.3) NIV ⁵ ; 2 (1.5%); 43 (41·2%); 3.5 duration (days) 18.0 (2.0) 6.8 (2.3) Invasive ventilation ⁵ ; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support ⁵ ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ⁵ ; 13 (12%); 59 (56.4%); 0.01 Novel Remdesivir 0 (0%) 12 (11.5%)
ALT/SGPT (IU/L) 58.7 (69.7) 97.6 (82.3) 0.007 Creatinine (mg/dl) 1.3 (2.6) 1.1 (0.5) 0.5 CTSS 23·2 (11·5) 29.5 (6.7) 0.005 Supplementation required ⁵ ; 12 (11·2%); 85 (81.8%); 0.5 duration (days) 7.8 (7.1) 8.1 (3.1) HFNC ⁵ ; 6 (5.6%); 12 (11.4%); 1.2 duration (days) 10.1 (6.2) 7.2 (4.3) NIV ⁵ ; 2 (1.5%); 43 (41.2%); 3.5 duration (days) 18.0 (2.0) 6.8 (2.3) Invasive ventilation ⁵ ; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support ⁵ ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ⁵ ; 13 (12%); 59 (56.4%); 0.01 Novel Remdesivir 0 (0%) 12 (11.5%)
Creatinine (mg/dl) 1.3 (2.6) 1.1 (0.5) 0.5 CTSS 23·2 (11·5) 29.5 (6.7) 0.005 Supplementation
CTSS 23·2 (11·5) 29.5 (6.7) 0.005 Supplementation required ⁵ ; 12 (11·2%); 85 (81.8%); 0.5 HFNC ⁵ ; 6 (5.6%); 12 (11·4%); 1.2 duration (days) 10.1 (6.2) 7.2 (4.3) NIV ⁵ ; 2 (1.5%); 43 (41.2%); 3.5 Invasive ventilation ⁵ ; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support ⁵ ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ⁵ ; 13 (12%); 59 (56.4%); 0.01 Novel Remdesivir 0 (0%) 12 (11.5%)
Supplementation required ^{\$} ; 12 (11·2%); 85 (81.8%); 0.5 duration (days) 7.8 (7.1) 8.1 (3.1) HFNC ^{\$} ; 6 (5.6%); 12 (11·4%); 1.2 duration (days) 10.1 (6.2) 7.2 (4.3) NIV ^{\$} ; 2 (1.5%); 43 (41·2%); 3.5 duration (days) 18.0 (2.0) 6.8 (2.3) 0.002 Invasive ventilation ^{\$} ; 1 (0.9%); 25 (24·3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) 0.01 Ionotropic support ^{\$} ; 1 (0.9%); 25 (24·3%); 0.01 duration (days) 11 (0) 4.2 (1.4) 0.01 ICU/HDU admissions ^{\$} ; 13 (12%); 59 (56·4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6) Novel Remdesivir 0 (0%) 12 (11.5%)
required ^{\$} ; 12 (11·2%); 85 (81.8%); 0.5 duration (days) 7.8 (7.1) 8.1 (3.1) HFNC ^{\$} ; 6 (5.6%); 12 (11.4%); 1.2 duration (days) 10.1 (6.2) 7.2 (4.3) NIV ^{\$} ; 2 (1.5%); 43 (41.2%); 3.5 duration (days) 18.0 (2.0) 6.8 (2.3) Invasive ventilation ^{\$} ; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support ^{\$} ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ^{\$} ; 13 (12%); 59 (56.4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6) Novel Remdesivir 0 (0%) 12 (11.5%)
duration (days) 7.8 (7.1) 8.1 (3.1) HFNC ^{\$} ; 6 (5.6%); 12 (11.4%); 1.2 duration (days) 10.1 (6.2) 7.2 (4.3) NIV ^{\$} ; 2 (1.5%); 43 (41.2%); 3.5 duration (days) 18.0 (2.0) 6.8 (2.3) Invasive ventilation ^{\$} ; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support ^{\$} ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ^{\$} ; 13 (12%); 59 (56.4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6) Novel Remdesivir 0 (0%) 12 (11.5%)
HFNC ^{\$} ; 6 (5.6%); 12 (11.4%); 1.2 duration (days) 10.1 (6.2) 7.2 (4.3) NIV ^{\$} ; 2 (1.5%); 43 (41.2%); 3.5 duration (days) 18.0 (2.0) 6.8 (2.3) Invasive ventilation ^{\$} ; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support ^{\$} ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ^{\$} ; 13 (12%); 59 (56.4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6) Novel Remdesivir 0 (0%) 12 (11.5%)
duration (days) NIV\$; 2 (1.5%); 43 (41.2%); 3.5 duration (days) 18.0 (2.0) 6.8 (2.3) Invasive ventilation\$; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support\$; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions\$; 13 (12%); 59 (56.4%); 0.01 duration (days) Novel Remdesivir 0 (0%) 12 (11.5%)
NIV\$; 2 (1.5%); 43 (41.2%); 3.5 duration (days) 18.0 (2.0) 6.8 (2.3) Invasive ventilation\$; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support\$; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions\$; 13 (12%); 59 (56.4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6) Novel Remdesivir 0 (0%) 12 (11.5%)
duration (days) Invasive ventilation ^{\$} ; 1 (0.9%); 25 (24.3%); 0.002 duration (days) Ionotropic support ^{\$} ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) I1 (0) ICU/HDU admissions ^{\$} ; 13 (12%); 59 (56.4%); 0.01 duration (days) Novel Remdesivir O (0%) 12 (11.5%)
Invasive ventilation ^{\$} ; 1 (0.9%); 25 (24.3%); 0.002 duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support ^{\$} ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ^{\$} ; 13 (12%); 59 (56.4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6) Novel Remdesivir 0 (0%) 12 (11.5%)
duration (days) 10.0 (0) 2.1 (1.6) Ionotropic support ^{\$} ; 1 (0.9%); 25 (24.3%); 0.01 duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ^{\$} ; 13 (12%); 59 (56.4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6) Novel Remdesivir 0 (0%) 12 (11.5%)
Ionotropic support ^{\$} ; 1 (0.9%); 25 (24.3%); 0.01 duration (days)
duration (days) 11 (0) 4.2 (1.4) ICU/HDU admissions ^{\$} ; 13 (12%); 59 (56.4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6) Novel Remdesivir 0 (0%) 12 (11.5%)
ICU/HDU admissions ^{\$} ; 13 (12%); 59 (56.4%); 0.01 duration (days) 10.2 (7.8) 15.4 (8.6) Novel Remdesivir 0 (0%) 12 (11.5%)
duration (days) 10.2 (7.8) 15.4 (8.6)
Novel Remdesivir 0 (0%) 12 (11.5%)
35 31 dt \$
Medications ^{\$} II-6 inhibitor 0 (0%) 0 (0%)
Convalescent plasma 0 (0%) 1 (1%)
Steroids 4 (4%) 75 (72.1%)
Antibiotics ^{\$} Azithromycin 50 (47%) 81 (78.2%)
Ceftriaxone 15 (14%) 17 (16%)
Amoxicillin-Clavulanic 3 (3%) 33 (32%) acid

Data are mean (SD) unless stated otherwise

^{*}Data are expressed as number (percentage)

SD: Standard Deviation; TLC: Total Leucocyte Count; mm3: millimeter cubed; Hb: Hemoglobin; gm/dl: grams per deciliter; NLR: Neutrophil Lymphocyte Ratio; INR: International Normalized Ratio; AST/SGOT: Aspartate Amino-transaminase/ Serum Glutamic-oxaloacetic Transaminase; ALT/SGPT: Alanine Amino-transaminase/ Serum Glutamic-pyruvic Transaminase; CTSS: CT severity score (calculated with the minimum of 0 and the maximum value of 40); HFNC: High Flow Nasal Cannula; NIV: Non-Invasive Ventilation; ICU: Intensive care unit; HDU: High Dependency Unit; IL-6 Interleukin-6

Table 4: Complications and outcomes of patients during both COVID-19 waves			
Variable	Sub-group	First Wave (W1) n=106	Second Wave (W2) n=104
Complications	Bacterial pneumonia	1 (0.9%)	9 (9%)
	ARDS	7 (6.4%)	51 (48.7%)
	Pleural effusion	0 (0%)	3 (2.5%)
	MI	2 (1.8%)	3 (2.5%)
	Pulmonary embolism	0 (0%)	0 (0%)
	AKI	3 (2.5%)	19 (18%)
	ALI	7 (6.4%)	13 (12.8%)
	Hyperglycemia	10 (9.6%)	15 (14%)
Outcome	Discharge	96 (90.4%)	74 (71%)
	Death	10 (9.6%)	30 (29%)

Data are expressed as number (percentage)

ARDS: Acute Respiratory Distress Syndrome MI: Myocardial Infarction, AKI: Acute Kidney Injury, ALI: Acute Liver Injury

Discussion

The COVID-19 pandemic, although contained in some parts of the world, is still re-emerging in many countries, especially this second wave. This has led to the re-introduction of lockdown in some countries.⁶ This shows that still, we are far away from altogether tackling this pandemic. The second wave of COVID hitting India is in many ways different from the first.

In this large-scale retrospective study, we have analyzed the major differences between COVID W1 and W2. In W2, patients are presenting with more dyspnea (80% v/s 15%) and hypoxia

[Spo2 84-0 (13-4)% v/s 91-9 (7-4)%]. This has large logistics implications for developing countries like India. Hence, we recommend urgent commission of oxygen plants so that these upcoming oxygen demands can be met. 70.2% of the cases in W2 have the severe disease compared with 37.5% in W1; thus, ICU admissions are more in W2 (56.4%) than W1 (12.0%). Differences are most likely due to varying demographic structures and virus strain characteristics, among other factors. The novel coronavirus has differential dissemination; hence, certain regions have a higher disease burden than others for reasons not understood. After acquiring a vast sea of data from various trials, we also found that hospitals in W2 are utilizing various novel therapies like remdesivir (11.3% v/s 0%) and steroids (72.1% v/s 4%) in higher frequencies as compared with W1. However, this has associated complications too, like hyperglycemia (14% v/s 9.6%) and a dreaded infection rapidly rising in the immunocompromised COVID patients in India, Mucormycosis.⁷

The W2 has worse outcomes too. Incidence of acute respiratory distress syndrome (48.7% v/s 6.45), acute kidney injury (18% v/s 2.4%), acute liver injury (12.8% v/s 6.4%), and deaths (29% v/s 9.6%) is higher in W2. All these suggest that W2 is hitting India harder than W1; hence timely action is the need of the hour to accommodate the different demographic distribution of the second wave of COVID infection in India utilizing proper social distancing and sanitizing protocols. The higher levels of SGOT and SGPT values in W2 need to be studied further. In addition, frequent monitoring of routine blood investigations must be done to watch for renal/hepatic/other organ dysfunction, which may add to the list of poor prognostic factors in COVID-19.

Our study has limitations. We only analyzed the records of the hospitalized patients; hence, we could not take into account any non-hospitalized COVID-19 patient with mild disease.

Moreover, because of hospital bias, the proportion of severe cases is higher in W2 than W1. The

primary reason for this being a change in the admission criteria from W1 to W2. In W1, the

hospital had the policy of admitting all COVD-19 positive patients. However, with the rising

number of cases and decreasing bed availability in W2, the hospital admits a predominating

number of moderate and severe cases. In addition, the use of experimental therapies has appeared

midway after the first wave in India, which is why their proportion of use is more in W2.

In conclusion, the second wave of COVID has hit India hard and can overwhelm India's

healthcare infrastructure. Hypoxia and organ dysfunctions are more frequently reported in the

second wave population, leading to higher ICU admissions and deaths, further overburdening the

situation. Our data could be used to inform India's population about the severity of this second

wave so that people understand the nature of the situation and follow all the COVID-19

appropriate behaviors more strictly. The lessons learned from this fight are essential to prevent a

third wave from entering any country. We should be better prepared in terms of testing,

vaccination, and boosting our critical care sector.

Contributors

MK contributed to the data collection, data analysis, and was involved in manuscript writing.

BOS, PD, and AK contributed to the data collection and were involved in reviewing the draft.

PKP gave the concept, interpreted analysis, critically reviewed the draft, and approved it for

publication along with all authors.

Data sharing

It will be made available to others as required upon requesting the corresponding author.

Acknowledgment

None

Conflicts of interest

We declare that we have no conflicts of interest.

Funding source

None

References

- Explained: What has changed in second wave of Covid-19? | Explained News, The Indian Express. https://indianexpress.com/article/explained/explained-whats-changed-in-second-wave-7289002/. Accessed May 25, 2021.
- 2. PANGO lineages. https://cov-lineages.org/lineages/lineage_B.1.617.html. Accessed May 25, 2021.
- 3. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727-11734. doi:10.1073/pnas.2003138117
- Mortality Analyses Johns Hopkins Coronavirus Resource Center.
 https://coronavirus.jhu.edu/data/mortality. Accessed May 25, 2021.
- 5. Clinical management protocol for Covid-19 (In Adults). Government of India, Ministry of Health and Family Welfare. Version 6. 24.05.21. https://ndma.gov.in/sites/default/files/PDF/covid/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf Accessed May 25, 2021.
- 6. England imposes new national lockdown to combat COVID-19 resurgence | Reuters.

- https://www.reuters.com/article/uk-health-coronavirus-britain-lockdown/england-imposes-new-national-lockdown-to-combat-covid-19-resurgence-idUKKBN27G0TM?edition-redirect=uk. Accessed May 25, 2021.
- 7. Mucormycosis: The "black fungus" maiming Covid patients in India BBC News. https://www.bbc.com/news/world-asia-india-57027829. Accessed May 25, 2021.
- 8. Job S, Kapoor M, Panda PK, Mohan L, Ravikant . COVID-19 Prevention Protocol for an Organised Mass Gathering-An Essential Requisite in Pandemic and Post-Pandemic Phase. *J Clin Diagnostic Res.* 2021. doi:10.7860/JCDR/2021/47856.14713